

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578409410US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 11, 2003

Signature: *Monica L. Thomas*

(Monica L. Thomas)

Docket No.: HO-P01899US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Huda Y. Zoghbi

Application No.: 09/585,645

Group Art Unit: 1633

Filed: June 1, 2000

Examiner: Qian, Celine X.

For: **COMPOSITIONS AND METHODS FOR
THE THERAPEUTIC USE OF AN ATONAL-
ASSOCIATED SEQUENCE FOR
DEAFNESS, OSTEOARTHRITIS AND
ABNORMAL CELL PROLIFERATION**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of each reference on PTO/SB/08 is attached.

The Examiner stated in the Advisory Action mailed February 11, 2003 that the Information Disclosure Statement (IDS) filed on January 21, 2003 failed to comply with 37 C.F.R. §1.97 (d) because it lacked a statement as specified in 37 C.F.R. §1.97 (e). Applicants state herein that no item of information contained therein was cited in a communication from a foreign patent office in a counterpart foreign application, and that no item cited therein was known more than three months prior to the filing of the IDS as pertaining to the prosecution of the present invention. The references were deemed necessary for citation only upon the course of prosecution of the application, and Applicants respectfully re-submit the IDS and corresponding references herewith.

25271916.1

RECEIVED

MAR 14 2003

TECH CENTER 1600/2900



While the information and references disclosed in this Supplemental Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


Although the fee was paid in the previous response filed January 21, 2003 for the IDS which was not considered, the Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P01899US2.

Dated:

March 11, 2003

Respectfully submitted,

By



Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)